Migraine presents a major public health burden in China, leading to impaired quality of life, widespread health loss, and loss of productivity for a sizeable population. Owing to migraine’s nonfatal nature, awareness about the disorder in China is low, particularly in the rural areas. Treatment of migraine is based on the use of older, generic drugs, such as rizatriptan, topiramate, flunarizine, diclofenac, and lomerizine. However, despite the availability of several such drugs, a significant unmet need exists for more-efficacious and prophylactic therapies for migraine. We expect that several novel therapies for migraine will launch during the forecast period in China, leading to significant market growth. Moreover, we expect ongoing reforms in China’s regulatory and A&R landscape to encourage MNCs to enter the migraine market.
1. How large is China’s drug-treatable migraine population, and how will the drug-treatment rate change during the forecast period?
2. Which are the most commercially relevant drugs in China’s migraine market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
3. What are the key market access considerations for key therapies in the migraine pipeline in China? What is their potential in terms of sales/uptake in migraine? What are interviewed experts’ opinions on these key emerging therapies?
4. What are the key drivers and constraints in the Chinese migraine market, and how will the market evolve over the forecast period?
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 52 surveys with neurologists and PCPs. Supported by survey data collected for this and other DRG research
Diagnosed prevalence of migraine in urban versus rural China; clinically relevant and market-relevant, drug-treatable populations
10-year, annualized, drug-level sales and patient shares of key migraine agents through 2029, based on primary and secondary market research to formulate bottom-up assumptions
Phase III/PR: 6 drugs; Phase II: 1 drug
- Migraine - Geographic Focus: China - Migraine - China In-Depth (China)
Author(s): Karan Verma, MSc; Shilpa Thakur
Karan is a Senior Analyst with the China-in-Depth team at Decision Resources Group, where he specializes in disease landscape and forecast reports based on a range of indications and therapy areas and focused specifically on the China healthcare market.
Before joining DRG, Karan was associated with Aranca, a boutique management consulting firm. Prior to that, he was working with Frost & Sullivan, a global healthcare consulting firm, where he was helping clients devise market entry strategies, conducting technology feasibility studies, and doing competitive intelligence for new product development. His prior experience also includes a short KTP program with the University of Southampton, UK. Karan has earned his MSc in Biomedical Engineering from the University of Warwick, and B.E. in Biomedical Engineering from Maharshi Dayanand University, Haryana, India.
Shilpa Thakur is a medical graduate with a M.P.H from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics. She specializes in developing epidemiological forecasts for the multiple indications within the DRG syndicated portfolio.
Prior to joining Decision Resources, she monitored HIV sentinel surveillance 2016-2017 in Himachal Pradesh. She also has worked on to see the patterns of Antimicrobial resistance in India.